Fig. 3From: Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspectiveICER scatter plot. ICER Incremental cost-effectiveness ratio, QALYs Quality-adjusted life years, CNY Chinese YuanBack to article page